Forecast: Domestic Private Health Expenditure Per Capita in India 2023 - 2027 Discover more data with ReportLinker!

In 2023, the United States had the highest per capita health expenditure among OECD countries. At that time, per capita health expenditure in the U.S. amounted over ****** U.S. dollars, significantly higher than in Switzerland, the country with the second-highest per capita health expenditure. Norway, Germany and Austria are also within the top five countries with the highest per capita health expenditure. The United States also spent the highest share of it’s gross domestic product on health care, with **** percent of its GDP spent on health care services. Health Expenditure in the U.S. The United States is the highest spending country worldwide when it comes to health care. In 2022, total health expenditure in the U.S. exceeded **** trillion dollars. Expenditure as a percentage of GDP is projected to increase to approximately ** percent by the year 2031. Distribution of Health Expenditure in the U.S. Health expenditure in the United States is spread out across multiple categories such as nursing home facilities, home health care, and prescription drugs. As of 2022, the majority of health expenditure in the United States was spent on hospital care, accounting for a bit less than *** third of all health spending. Hospital care was followed by spending on physician and clinical services which accounted for ** percent of overall health expenditure.

The average for 2021 based on 19 countries was 3215.44 U.S. dollars. The highest value was in the USA: 11999.09 U.S. dollars and the lowest value was in India: 75.55 U.S. dollars. The indicator is available from 2000 to 2023. Below is a chart for all countries where data are available.

Filipinos spent about ****** Philippine pesos on health in 2024, indicating growth from the previous year. The National Capital Region had the highest health expenditures in that year. Rising current health expenditures The country’s health spending has been steadily rising in the past few years, reaching its peak value in 2024. Increased healthcare spending was particularly noted between 2020 and 2021 when the COVID-19 pandemic hit, as Filipinos purchased more essential health products and medicines to better protect themselves from the virus. Factors contributing to increased health spending In addition to the coronavirus pandemic, high inflation rates in the Philippines between 2022 and 2023, fueled the increasing prices of medicines and other pharmaceutical goods. To lower the prices of medicines, the government has been encouraging foreign pharmaceutical firms to establish facilities in the country to increase local production. Discussions were being held between pharmaceutical firms such as in India, which was the leading source of pharmaceutical imports to the Philippines.

Among OECD member countries, the United States had the highest percentage of gross domestic product spent on health care as of 2023. The U.S. spent nearly ** percent of its GDP on health care services. Germany, France and Japan followed the U.S. with distinctly smaller percentages. The United States had both significantly higher private and public spending on health compared with other developed countries. Why compare OECD countries?OECD stands for Organization for Economic Co-operation and Development. It is an economic organization consisting of ** members, mostly high-income countries and committed to democratic principles and market economy. This makes OECD statistics more comparable than statistics of developed and undeveloped countries. Health economics is an important matter for the OECD, even more since increasing health costs and an aging population have become an issue for many developed countries. Health costs in the U.S.  A higher GDP share spent on health care does not automatically lead to a better functioning health system. In the case of the U.S., high spending is mainly because of higher costs and prices, not due to higher utilization. For example, physicians’ salaries are much higher in the U.S. than in other comparable countries. A doctor in the U.S. earns almost twice as much as the average physician in Germany. Pharmaceutical spending per capita is also distinctly higher in the United States. Furthermore, the U.S. also spends more on health administrative costs compare to other wealthy countries.

India's expenditure on health - total government (public) and private expenditure per capita and as % of GDP, and comparison with global peers.

In financial year 2022, the northern state of Uttar Pradesh had the highest total health expenditure, valued at more than 1098 billion Indian rupees in India. Comparatively, Uttarakhand had the lowest total healthcare expenditure of around ** billion rupees.

The global current health expenditure as a share of the GDP in was forecast to continuously increase between 2024 and 2029 by in total *** percentage points. After the seventh consecutive increasing year, the share is estimated to reach **** percent and therefore a new peak in 2029. According to Worldbank health spending includes expenditures with regards to healthcare services and goods. It is depicted here in relation to the total gross domestic product (GDP) of the country or region at hand.The shown data are an excerpt of Statista's Key Market Indicators (KMI). The KMI are a collection of primary and secondary indicators on the macro-economic, demographic and technological environment in up to *** countries and regions worldwide. All indicators are sourced from international and national statistical offices, trade associations and the trade press and they are processed to generate comparable data sets (see supplementary notes under details for more information).Find more key insights for the current health expenditure as a share of the GDP in countries like North America and the Americas.

India MPCE: WI: MMRP: Urban: Non-food: Medical data was reported at 409.000 INR in 2024. This records an increase from the previous number of 382.000 INR for 2023. India MPCE: WI: MMRP: Urban: Non-food: Medical data is updated yearly, averaging 395.500 INR from Jul 2023 (Median) to 2024, with 2 observations. The data reached an all-time high of 409.000 INR in 2024 and a record low of 382.000 INR in 2023. India MPCE: WI: MMRP: Urban: Non-food: Medical data remains active status in CEIC and is reported by Ministry of Statistics and Programme Implementation. The data is categorized under Global Database’s India – Table IN.HB005: HCES: Modified Mixed Reference Period (MMRP): Average Monthly Per Capita Consumption Expenditure (MPCE): by Item Group: Urban.

India MPCE: MMRP: Rural: Non-food: Medical data was reported at 282.000 INR in 2024. This records an increase from the previous number of 269.000 INR for 2023. India MPCE: MMRP: Rural: Non-food: Medical data is updated yearly, averaging 275.500 INR from Jul 2023 (Median) to 2024, with 2 observations. The data reached an all-time high of 282.000 INR in 2024 and a record low of 269.000 INR in 2023. India MPCE: MMRP: Rural: Non-food: Medical data remains active status in CEIC and is reported by Ministry of Statistics and Programme Implementation. The data is categorized under Global Database’s India – Table IN.HB004: HCES: Modified Mixed Reference Period (MMRP): Average Monthly Per Capita Consumption Expenditure (MPCE): by Item Group: Rural.

According to Cognitive Market Research, the global Venous Stents Market size will be USD 1849.2 million in 2025. It will expand at a compound annual growth rate (CAGR) of 7.50% from 2025 to 2033.

North America held the major market share for more than 37% of the global revenue with a market size of USD 684.20 million in 2025 and will grow at a compound annual growth rate (CAGR) of 5.3% from 2025 to 2033.
Europe accounted for a market share of over 29% of the global revenue with a market size of USD 536.27 million.
APAC held a market share of around 24% of the global revenue with a market size of USD 443.81 million in 2025 and will grow at a compound annual growth rate (CAGR) of 9.5% from 2025 to 2033.
South America has a market share of more than 4% of the global revenue with a market size of USD 70.27 million in 2025 and will grow at a compound annual growth rate (CAGR) of 6.5% from 2025 to 2033.
Middle East had a market share of around 4% of the global revenue and was estimated at a market size of USD 73.97 million in 2025 and will grow at a compound annual growth rate (CAGR) of 6.8% from 2025 to 2033.
Africa had a market share of around 2.2% of the global revenue and was estimated at a market size of USD 40.68 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.2% from 2025 to 2033.
Wallstent Technology category is the fastest growing segment of the Venous Stents Market

Market Dynamics of Venous Stents Market

Key Drivers for Venous Stents Market

Increased Healthcare Expenditure

Rising global healthcare spending is playing a crucial role in advancing access to advanced medical devices, including venous stents. As governments and private sectors allocate more funds toward improving healthcare infrastructure, particularly in emerging economies, the availability of sophisticated vascular interventions is expanding. In countries such as China, India, and Brazil, rising per capita income and supportive public health initiatives are increasing investments in tertiary care and cardiovascular facilities. Additionally, the surge in private hospitals and insurance coverage in developing regions has created a broader patient base capable of affording venous stent procedures. In high-income countries, continuous funding toward innovation, training, and clinical trials further accelerates product adoption. Overall, higher expenditure leads to better diagnostic access, skilled specialists, and availability of next-generation venous stenting technologies, reinforcing market growth. For instance, according to U.S. Centers for Medicare & Medicaid Services, in 2023, US healthcare spending reached $4.9 trillion, with expenditures per capita at $14,570. This represents a 7.5% increase from the previous year and accounted for 17.6% of the nation's Gross Domestic Product (GDP).

https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/historicalGrowing Adoption of Minimally Invasive Procedures

The healthcare industry’s increasing focus on minimally invasive procedures (MIPs) has significantly influenced the adoption of venous stents. Compared to traditional open surgery, venous stenting offers lower procedural risks, reduced pain, shorter hospital stays, and faster recovery times. Patients and physicians alike are drawn to these advantages, especially in aging populations or those with comorbidities that make invasive surgery less feasible. Advancements in interventional radiology and endovascular techniques have further made these procedures safer and more accessible. This trend is also aligned with value-based care models that emphasize cost-efficiency and improved outcomes. Moreover, increasing awareness and acceptance of catheter-based interventions by both practitioners and patients is accelerating procedural volume, thereby boosting market demand for high-performance venous stents designed for percutaneous deployment and optimized vessel support.

Restraint Factor for the Venous Stents Market

High Cost of Procedures

The high cost associated with venous stenting procedures remains a significant barrier, particularly in low- and middle-income countries. The total expense includes the stent device, imaging guidance systems, specialized interventional staff, hospital infrastructure, and postoperative care. For patients without comprehensive insurance coverage, these costs can be prohibitive, discouraging t...

The Asia-Pacific syringe market, valued at $4.09 billion in 2025, is projected to experience robust growth, driven by a compound annual growth rate (CAGR) of 9.23% from 2025 to 2033. This expansion is fueled by several key factors. Rising prevalence of chronic diseases like diabetes and osteoarthritis necessitates increased syringe usage for medication delivery. The growing adoption of safety syringes, designed to minimize needle-stick injuries for healthcare professionals, is another significant driver. Furthermore, the increasing demand for prefillable syringes in pharmaceutical manufacturing and the expanding healthcare infrastructure across the region contribute to market growth. Specific growth within segments is expected to be influenced by factors such as government initiatives promoting safe injection practices, technological advancements in syringe design and manufacturing, and increasing disposable incomes leading to greater affordability of healthcare products. The market is segmented by usability (sterilizable, disposable), material (glass, plastic), type (general, specialized), and application (diabetes, Botox, etc.), with disposable plastic syringes in the general application segment expected to command a substantial share. Key players such as Becton Dickinson, Hindustan Syringes, and Terumo Corporation are shaping the market through innovation and strategic partnerships. While regulatory hurdles and fluctuations in raw material prices pose potential challenges, the overall outlook remains positive, particularly in rapidly developing economies like India and China. Geographical distribution of market value within Asia-Pacific will likely show China and India as leading consumers, driven by large populations and increasing healthcare expenditure. Japan and South Korea will also contribute significantly due to their advanced healthcare systems and high per capita income. However, the “Rest of Asia-Pacific” segment will likely experience considerable growth as healthcare infrastructure improves and awareness of disease management increases. The market will continue to evolve with a focus on improving safety, efficacy, and convenience for both patients and healthcare providers. Innovation in areas such as smart syringes and improved disposal mechanisms is expected to further fuel market expansion. Recent developments include: June 2023: Shilpa Biologicals Private Limited (SBPL), a wholly owned subsidiary of Shilpa Medicare Limited (SML), received the Marketing Authorization Permission for its Adalimumab injection in a prefilled syringe (PFS) in India, a biosimilar of adalimumab higher concentration formulation in India. This is used for the treatment of rheumatoid arthritis., May 2023: SHL Medical exhibited Molly modular platform autoinjectors with pre-installed Needle Isolation Technology (NIT) at the Convention on Pharmaceutical Ingredients (CPHI) Japan in 2023.. Key drivers for this market are: Rising Prevalance of Chronic and Infectious Diseases, Increasing Vaccination Programs; Increasing Trend of Self-Administration of Injections and Greater Dose Precision in Injections. Potential restraints include: Rising Prevalance of Chronic and Infectious Diseases, Increasing Vaccination Programs; Increasing Trend of Self-Administration of Injections and Greater Dose Precision in Injections. Notable trends are: The Pre-Filled Syringes Segment is Expected to Witness a Significant Growth in the Syringe Market During the Forecast Period.

Pharmaceutical spending per capita in Canada stood at nearly 900 U.S. dollars in 2023 (constant prices). In comparison, the United States reported per capita spending of nearly 1,500 U.S. dollars. As for medical goods and services in general, the U.S. is among the countries with the highest health costs worldwide. The higher costs in the United States are particularly obvious when compared to other high-income, developed countries. Higher drug prices in the U.S.Higher spending on pharmaceuticals is less impacted by higher drug usage by Americans and more by significantly higher drug prices in the United States. While in other countries, drug prices are regulated more or less by governments, the U.S. leaves drug pricing to market competition. As an outcome, the U.S. market is the most profitable for pharmaceutical companies. For example, the price for blockbuster drug Humira was six times higher in the United States than in Germany (2022). Rx drug usage in the U.S.Almost half of all Americans have taken at least one prescription medicine within the preceding month. Generally, women take more prescribed drugs than men, although the difference decreased significantly over the past two decades. In the United States, among the therapeutic areas where spending is the highest are diabetes, oncology, autoimmune, and respiratory diseases. On the other hand, antihypertensives and mental health drugs are the leading classes based on number of prescriptions filled.

MMRP：MPCE：WI：城镇：非食品：医疗在07-01-2024达409.000印度卢比，相较于07-01-2023的382.000印度卢比有所增长。MMRP：MPCE：WI：城镇：非食品：医疗数据按年更新，07-01-2023至07-01-2024期间平均值为395.500印度卢比，共2份观测结果。该数据的历史最高值出现于07-01-2024，达409.000印度卢比，而历史最低值则出现于07-01-2023，为382.000印度卢比。CEIC提供的MMRP：MPCE：WI：城镇：非食品：医疗数据处于定期更新的状态，数据来源于Ministry of Statistics and Programme Implementation，数据归类于全球数据库的印度 – Table IN.HB005: HCES: Modified Mixed Reference Period (MMRP): Average Monthly Per Capita Consumption Expenditure (MPCE): by Item Group: Urban。